Treatment of diastolic dysfunction in hypertension

Keyphrases

• Hypertension 100%
• Diastolic Dysfunction 100%
• Heart Failure 60%
• Cardiovascular Mortality 40%
• Diastolic Function 40%
• Life Studies 40%
• Diastolic Heart Failure 40%
• Patient Management 20%
• High Prevalence 20%
• Hypertension Management 20%
• Pathophysiology 20%
• Cardiac Function 20%
• Beta-blockers 20%
• Treatment Complications 20%
• Associated Complications 20%
• Hypertensive Patients 20%
• Pharmacologic Interventions 20%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 20%
• Angiotensin Receptor Blockers 20%
• Heart Failure Hospitalization 20%
• Spironolactone 20%
• Cardiovascular Morbidity 20%
• Calcium Channel Blockers 20%
• Heart Failure with Preserved Ejection Fraction (HFpEF) 20%
• Hypertension Prevalence 20%
• Losartan 20%
• Patients with Hypertension 20%
• Diuretics 20%
• Aldosterone Antagonists 20%
• Diastolic Filling 20%
• Points Reduction 20%
• Candesartan 20%
• Charm 20%
• TOPCAT 20%
• Failure Assessment 20%
• Aborted Cardiac Arrest 20%
• Cardiac Hospitalization 20%
• Irbesartan 20%
• In-treatment 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Diastolic Dysfunction 100%
• Congestive Heart Failure 80%
• Diastolic Heart Failure 40%
• Prevalence 20%
• Pathophysiology 20%
• Heart Arrest 20%
• Beta Adrenergic Receptor Blocking Agent 20%
• Calcium Channel Blocker 20%
• Dipeptidyl Carboxypeptidase Inhibitor 20%
• Cardiovascular Mortality 20%
• Losartan 20%
• Angiotensin Receptor Antagonist 20%
• Aldosterone Antagonist 20%
• Spironolactone 20%
• Heart Failure with Preserved Ejection Fraction 20%
• Candesartan 20%
• Irbesartan 20%
• Diuretics 20%